FINCH THERAPEUTICS GROUP INC (FNCH) Stock Price, Quote, News and Overview
NASDAQ:FNCH - Nasdaq - US31773D2009 - Common Stock - Currency: USD
FNCH Quote, Performance and Key Statistics
1.8
-0.18 (-9.09%)
The current stock price of FNCH is 1.8 USD. In the past month the price decreased by -22.41%. In the past year, price decreased by -78.26%.
FNCH Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.65 | 338.30B | ||
| AMGN | AMGEN INC | 14.31 | 159.72B | ||
| GILD | GILEAD SCIENCES INC | 14.48 | 139.43B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 121.30B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.88 | 61.61B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 41.17B | ||
| ARGX | ARGENX SE - ADR | 97.61 | 34.27B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.44 | 27.29B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.68B | ||
| NTRA | NATERA INC | N/A | 21.60B | ||
| BIIB | BIOGEN INC | 8.41 | 19.50B | ||
| INSM | INSMED INC | N/A | 19.33B |
Related stock screener links
About FNCH
Company Profile
Finch Therapeutics Group, Inc. engages in the development of microbiome drugs. The company is headquartered in Boston, Massachusetts and currently employs 18 full-time employees. The company went IPO on 2021-03-19. The company is focused on realizing the value of its intellectual property estate and other assets, while supporting the advancement of its microbiome technology through partnerships and collaborations. The company has an intellectual property estate, including more than 70 issued U.S. and foreign patents with relevance for both donor-derived and donor-independent microbiome therapeutics in a range of potential indications. The Company’s assets include CP101, an orally administered microbiome candidate designed for the prevention of recurrent C. difficile infection (CDI), with positive clinical data from a Phase II randomized, placebo-controlled trial and a Phase II open-label trial, and pre-clinical assets that are designed to target ulcerative colitis, Crohn’s disease, and autism spectrum disorder. Additionally, it has also developed a biorepository of strains and samples.
Company Info
FINCH THERAPEUTICS GROUP INC
75 State Street, Suite 100
Boston MASSACHUSETTS US
Employees: 18
Phone: 16172296499
FINCH THERAPEUTICS GROUP INC / FNCH FAQ
What is the stock price of FINCH THERAPEUTICS GROUP INC today?
The current stock price of FNCH is 1.8 USD. The price decreased by -9.09% in the last trading session.
What is the ticker symbol for FINCH THERAPEUTICS GROUP INC stock?
The exchange symbol of FINCH THERAPEUTICS GROUP INC is FNCH and it is listed on the Nasdaq exchange.
On which exchange is FNCH stock listed?
FNCH stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for FINCH THERAPEUTICS GROUP INC stock?
7 analysts have analysed FNCH and the average price target is 91.8 USD. This implies a price increase of 5000% is expected in the next year compared to the current price of 1.8. Check the FINCH THERAPEUTICS GROUP INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is FINCH THERAPEUTICS GROUP INC worth?
FINCH THERAPEUTICS GROUP INC (FNCH) has a market capitalization of 2.90M USD. This makes FNCH a Nano Cap stock.
How many employees does FINCH THERAPEUTICS GROUP INC have?
FINCH THERAPEUTICS GROUP INC (FNCH) currently has 18 employees.
What are the support and resistance levels for FINCH THERAPEUTICS GROUP INC (FNCH) stock?
FINCH THERAPEUTICS GROUP INC (FNCH) has a resistance level at 2.23. Check the full technical report for a detailed analysis of FNCH support and resistance levels.
Is FINCH THERAPEUTICS GROUP INC (FNCH) expected to grow?
The Revenue of FINCH THERAPEUTICS GROUP INC (FNCH) is expected to decline by -100% in the next year. Check the estimates tab for more information on the FNCH EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy FINCH THERAPEUTICS GROUP INC (FNCH) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of FNCH, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of FNCH, evaluating the profitability, health, valuation and growth aspects
- FINCH THERAPEUTICS GROUP INC (FNCH) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- FINCH THERAPEUTICS GROUP INC (FNCH) Sales and EPS estimates to see what analysts future expectations are.
- FINCH THERAPEUTICS GROUP INC (FNCH) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- FINCH THERAPEUTICS GROUP INC (FNCH) Insider and Institutional Ownership to learn about the owners and their transactions.
- FINCH THERAPEUTICS GROUP INC (FNCH) Stock Chart to make your own analysis
- FINCH THERAPEUTICS GROUP INC (FNCH) Latest news and press-releases to stay up to date.
Does FINCH THERAPEUTICS GROUP INC (FNCH) stock pay dividends?
FNCH does not pay a dividend.
What is the Price/Earnings (PE) ratio of FINCH THERAPEUTICS GROUP INC (FNCH)?
FINCH THERAPEUTICS GROUP INC (FNCH) does not have a PE ratio as the earnings reported over the last twelve months were negative (-10.15).
What is the Short Interest ratio of FINCH THERAPEUTICS GROUP INC (FNCH) stock?
The outstanding short interest for FINCH THERAPEUTICS GROUP INC (FNCH) is 0.12% of its float. Check the ownership tab for more information on the FNCH short interest.
FNCH Technical Analysis
FNCH Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to FNCH. The financial health of FNCH is average, but there are quite some concerns on its profitability.
FNCH Financial Highlights
Over the last trailing twelve months FNCH reported a non-GAAP Earnings per Share(EPS) of -10.15. The EPS increased by 89.38% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -32.51% | ||
| ROE | -85.55% | ||
| Debt/Equity | 0 |
FNCH Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to FNCH. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 45.96% and a revenue growth -100% for FNCH